Company Overview and News

16
JP Morgan and Ford cancel plans for Saudi investor event

21h reuters
NEW YORK (Reuters) - JP Morgan & Chase Co (JPM.N) Chief Executive Jamie Dimon and Ford Motor Co (F.N) Chairman Bill Ford canceled plans to attend a Saudi investor conference, the companies said on Sunday, the latest such high-profile announcements after the disappearance of Saudi journalist Jamal Khashoggi.
GLSSP UGLD VIAB STAN SCBFF JBK DSLV CSSLF TFG CGBBW 2888 STAN DGLD CCF CS GS STAB STAC VIA C VIIX GSC VIIZ MA NYTAB GSJ CSGKF 580001 ZIV USLV TVIX GJS XIV

21
Weekly Commentary: Rude Awakening Coming

2018-10-14 seekingalpha
There's little satisfaction writing the CBB after a big down week in the markets. Motivation seems easier to come by after up weeks, perhaps my defiant streak kicking in. I find myself especially melancholy at the end of this week. There's a rude awakening coming - perhaps it's finally starting to unfold.
DGLD BATS 4162 CS FMCKI FMCKJ UGLD SCGLF UBS FMCCO FMCCP DSLV FMCCM VIIX FMCCN CSSLF VIIZ FMCCI FMCCJ SCGLY FMCCG FMCKO NYTAB FMCKP FMCKM FMCKN FMCKK FMCKL CSGKF NDAQ T FMCC 2007 ZIV USLV GLE TVIX FMCCS ULSGF FMCCT XIV

3
Dream of Tech Stocks Leading Asia Put to Test as Weighting Drops

2018-10-11 theedgemarkets
(Oct 12): The souring of U.S.-China relations amid rising trade tensions and hardware hacks are putting to test the dominance of technology companies on Asian stock markets.
CSGKF UGLD DSLV VIIX DGLD CSSLF VIIZ ZIV USLV TVIX CS XIV

3
Deutsche Bank, HSBC, Citi join new US$3.8 bil deal with Egypt

2018-10-11 theedgemarkets
CAIRO (Oct 11): Egypt struck a deal to get US$3.8 billion in new financing from an international consortium that includes Deutsche Bank AG and HSBC Bank Plc to boost its foreign-currency stockpile at a time when an emerging-market selloff is spooking investors.
11IE DSLV DB VIIX DGLD 42KM CSSLF VIIZ CS CSGKF UGLD 42MA ZIV USLV TVIX XIV

3
Decline in Asia dollar bond sales to spill into 2019 on yield woes, volatility

2018-10-08 bworldonline
ASIA’S dollar bond sales are set to end 2018 with a whimper after a sizzling start. Next year’s prospects may prove dimmer, bankers and investors say.
DSLV VIIX DGLD CSSLF VIIZ NAB NASXF NABZY CS NAUBF CSGKF UGLD ZIV USLV TVIX XIV

126
Oakmark Global Fund: Third Quarter 2018

2018-10-08 seekingalpha
Oakmark Global Fund – Investor Class Average Annual Total Returns (09/30/18) Since Inception (08/04/99) 10.18% 10–year 8.44% 5–year 6.33% 1–year 1.02% 3–month 0.09% Gross Expense Ratio as of 09/30/17 was 1.21% Net Expense Ratio as of 09/30/17 was 1.15%
NOV TPK MLUSG UGLD LLOBF RYAAY MTUAY MTUAF GE DSLV CSSLF USGPF ARNC DDAIF JBAXY GOOGL LLDTF TPRKY DGLD GOOG IPG CS BAC TVPKF GM USG ORCL JBARF GEC LLOY VIIX VIIZ RYAOF MA LYG NAPRF LLPH CSGKF LLPK LLPJ LLPE LLPD LLPG LLD5 GNE ZIV LLD7 LLPC USLV LLD6 TVIX LLD1 THC TV LLD2 XIV

3
IL&FS defaults could derail robust growth of NBFCs as stricter regulations soon to be in place

2018-10-08 financialexpress
The fastest pace of growth since 2013 at India’s non-bank financiers is about to come to a grinding halt. A spate of money market defaults by Infrastructure Leasing & Financial Services Ltd. has put the spotlight on non-bank finance companies. With banks struggling with bad loans and low capital buffers, non-bank lenders had rushed to tap demand for long-term financing to build roads, power plants and homes.
DSLV EDELWEISS VIIX DGLD CSSLF VIIZ IIFL 532922 532636 SRTRANSFIN CS 511218 CSGKF UGLD MAGMA SRRQY ZIV USLV 524000 TVIX XIV

13
Big Banks Aim to Show Higher Profits Still Ahead as Rates Rise

2018-10-07 theedgemarkets
But as the biggest U.S. banks report results that analysts estimate will set a new high for profitability this decade, shareholders are wondering: is this as good as gets, or is Jamie Dimon right that banks are entering a golden age.
BCS 83SF UGLD 83SK DSLV CSSLF CGBBW WFCNP DGLD CS 47MC WFC C VIIX VIIZ CSGKF ZIV USLV TVIX XIV

9
Credit Suisse Adopts Apple Business Chat for Asian Clients

2018-10-04 zacks
Credit Suisse Group AG (CS - Free Report) is adopting Apple Business Chat as a mode of communication with private banking clients in Singapore and Hong Kong, in a bid to upscale its digital offerings. With the help of this messaging service, customers will be able to know their account balance and portfolio or the status of their transactions, as of now.
WFCNP DGLD DNHBY HSNGF CS 0011 UGLD HSNGY WFC DSLV VIIX CSSLF VIIZ DNBHF CSGKF CSBR ZIV USLV TVIX XIV

38
Singapore Companies Are on a Global Acquisition Spree

2018-10-04 theedgemarkets
(Oct 4): Singapore Inc. is stirring, with companies from real estate to engineering becoming bolder in their hunt for acquisitions abroad.
BGX DGLD SGGKY BGLF CS UGLD SGPRF MON DSLV GEC GE SGPRY C VIIX CSSLF VIIZ BX BGB SGGKF CSGKF CGBBW TRI GNE ZIV USLV TVIX XIV

6
Credit Suisse (CS) Agrees With $10M Settlement for U.S. Probe

2018-10-01 zacks
Lately, legal hassles have heightened for Credit Suisse Group AG (CS - Free Report) , as the bank has been slapped with a fine of $10 million by the U.S. federal regulators. The company has been accused of malpractices related to its retail execution services business, including through Credit Suisse’s dark pool, amid ongoing scrutiny around the U.S. share trading industry. The Swiss Bank’s settlement resolves accusations related to improper treatment of customer orders from mid-2011 through March 2015.
BCS DGLD CS 83SF UGLD 83SK UBS FSLR 47MC DSLV VIIX CSSLF VIIZ CSGKF ZIV USLV TVIX RPM ULSGF XIV

3
Credit Suisse is fined $10 million in U.S. over customer orders

2018-09-28 reuters
NEW YORK (Reuters) - Credit Suisse Group AG (CSGN.S) was fined $10 million on Friday by the U.S. Securities and Exchange Commission and New York Attorney General Barbara Underwood over its handling of retail customer orders, including through its dark pool.
CSGKF UGLD DSLV VIIX DGLD CSSLF VIIZ ZIV USLV TVIX CS XIV

3
Credit Suisse settles with US regulators over electronic trading

2018-09-28 channelnewsasia
Credit Suisse Group AG has agreed to pay US$10 million to settle U.S. charges related to its handling of customer orders and alleged fraudulent electronic trading practices.
CSGKF UGLD DSLV VIIX DGLD CSSLF VIIZ ZIV USLV TVIX CS XIV

3
Credit Suisse settles with US regulators over electronic trading

2018-09-28 reuters
(Reuters) - Credit Suisse Group AG (CSGN.S) has agreed to pay $10 million to settle U.S. charges related to its handling of customer orders and alleged fraudulent electronic trading practices.
CSGKF UGLD DSLV VIIX DGLD CSSLF VIIZ ZIV USLV TVIX CS XIV

10
Goldman, JPMorgan, four others must face stock lending antitrust case

2018-09-28 channelnewsasia
NEW YORK: A U.S. judge on Thursday (Sep 27) ordered Goldman Sachs Group Inc , JPMorgan Chase & Co and four other large banks to face an antitrust lawsuit by investors who said they conspired to stifle competition in the nearly US$2 trillion stock lending market.
DGLD CS GS UGLD GLSSP UBS AOS MS JBK DSLV VIIX GSC CSSLF VIIZ TFG GSJ CSGKF ZIV USLV GJS TVIX ULSGF XIV

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 22542D829